Vutrisiran ATTR Cm denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Vutrisiran (ATTR-CM) for Medical Necessity — and How to Appeal

Vutrisiran (Amvuttra) is FDA-approved for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). A medical-necessity denial from Cigna means the plan's reviewing clinician determined that the documentation submitted does not satisfy the clinical criteria in Cigna's coverage policy. This is almost never a judgment that vutrisiran is inappropriate for ATTR-CM in general — it is a judgment that the submitted record did not demonstrate your specific case meets the plan's criteria. That distinction matters: the denial is about the documentation, not the drug.

## Why This Denial Is Appealable

Medical-necessity determinations must be based on clinical evidence, not administrative convenience. Under ACA §2719, you have the right to a full internal appeal and then an independent external review by a clinician with relevant expertise (typically a cardiologist or specialist in rare disease). Under ERISA §503 (for employer-sponsored plans), the plan must provide a full-and-fair review, including the specific clinical criteria applied and the clinical reviewer's reasoning. The external-review window is typically available for approximately four months after a final internal denial, and expedited review (often resolved within 72 hours) is available when delay would seriously jeopardize your health.

ATTR-CM is a progressive, life-threatening condition. Courts and external reviewers have consistently treated delays in coverage for serious conditions as heightening the scrutiny applied to medical-necessity denials.

## What to Gather

• Diagnosis confirmation: Technetium pyrophosphate or DPD nuclear scan report, cardiac biopsy pathology (if performed), genetic testing results (if hereditary), and cardiologist notes confirming ATTR-CM diagnosis and subtype.
• Functional and severity assessment: Recent cardiology notes documenting NYHA functional class, exercise tolerance, and disease progression.
• Prior-treatment history: Documentation of any prior or concurrent ATTR therapies, with dates, clinical rationale, and response.
• Prescriber medical-necessity letter: A detailed letter from your cardiologist explaining the diagnosis, the severity of disease, why vutrisiran is medically necessary, and how your case satisfies the FDA-approved labeling criteria and applicable ACC/AHA guidance.
• Cigna's coverage policy: Request the exact written criteria Cigna applied so your appeal addresses each point directly.

## Criteria-Mapping Structure

For each criterion in Cigna's medical policy, provide a direct evidentiary response:

> Cigna criterion: [paste verbatim] > Chart evidence: [exact date, test result, or physician note from your record]

## Timeline

File your internal appeal immediately — confirm the exact deadline in your denial letter. Request expedited review in writing given disease severity. After a final internal denial, file for external review promptly to preserve your rights.